BFM
ESPR

Boothbay Fund Management’s Esperion Therapeutics ESPR Stock Holding History

Boothbay Fund Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.8K Buy
+30,000
New +$83.9K ﹤0.01% 2058
2024
Q4 		– Sell
-44,909
Closed -$74.1K – 1615
2024
Q3 		$74.1K Hold
44,909
– – ﹤0.01% 1480
2024
Q2 		$99.7K Sell
44,909
-2,462
-5% -$5.79K ﹤0.01% 1351
2024
Q1 		$127K Sell
47,371
-49,362
-51% -$120K ﹤0.01% 1394
2023
Q4 		$289K Sell
96,733
-269,565
-74% -$350K 0.01% 1200
2023
Q3 		$359K Buy
366,298
+32,031
+10% +$46.3K 0.01% 1184
2023
Q2 		$465K Buy
334,267
+70,175
+27% +$98K 0.01% 1128
2023
Q1 		$420K Buy
264,092
+30,657
+13% +$158K 0.01% 1326
2022
Q4 		$1.45M Sell
233,435
-29,623
-11% -$212K 0.03% 737
2022
Q3 		$1.76M Sell
263,058
-8,485
-3% -$58.3K 0.04% 629
2022
Q2 		$1.73M Buy
+271,543
New +$1.54M 0.05% 604

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Boothbay Fund Management's ESPR Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 30,000 shares worth $94.8K. The stake represents ﹤0.01% of the portfolio and ranks #2058 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in ESPR as recently as Q3 2024.

Boothbay Fund Management first reported a position in ESPR in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.76M in Q3 2022. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Boothbay Fund Management held 30,000 shares of Esperion Therapeutics worth $94.8K as of Q2 2026.
  • Esperion Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2058 holding.
  • Boothbay Fund Management first reported a position in Esperion Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Boothbay Fund Management's Esperion Therapeutics position peaked at $1.76M in Q3 2022.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.